Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC

Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy.

Errataetall:

UpdateOf: medRxiv. 2020 Dec 04;:. - PMID 33300012

Media Type:

Electronic Article

Year of Publication:

2021

Contained In:

JCI insight - Vol. 6, No. 4 (2021)

Language:

English

Contributors:

Yoon, Hyun Ah
Bartash, Rachel
Gendlina, Inessa
Rivera, Johanna
Nakouzi, Antonio
Bortz, Robert H
Wirchnianski, Ariel S
Paroder, Monika
Fehn, Karen
Serrano-Rahman, Leana
Babb, Rachelle
Sarwar, Uzma N
Haslwanter, Denise
Laudermilch, Ethan
Florez, Catalina
Dieterle, M Eugenia
Jangra, Rohit K
Fels, J Maximilian
Tong, Karen
Mariano, Margarette C
Vergnolle, Olivia
Georgiev, George I
Herrera, Natalia G
Malonis, Ryan J
Quiroz, Jose A
Morano, Nicholas C
Krause, Gregory J
Sweeney, Joseph M
Cowman, Kelsie
Allen, Stephanie
Annam, Jayabhargav
Applebaum, Ariella
Barboto, Daniel
Khokhar, Ahmed
Lally, Brianna J
Lee, Audrey
Lee, Max
Malaviya, Avinash
Sample, Reise
Yang, Xiuyi A
Li, Yang
Ruiz, Rafael
Thota, Raja
Barnhill, Jason
Goldstein, Doctor Y
Uehlinger, Joan
Garforth, Scott J
Almo, Steven C
Lai, Jonathan R
Gil, Morayma Reyes
Fox, Amy S
Chandran, Kartik
Wang, Tao
Daily, Johanna P
Pirofski, Liise-Anne

Links:

Volltext

Keywords:

Adult
Age Factors
Aged
Aged, 80 and over
Antibodies, Neutralizing
Antibodies, Viral
COVID-19
Comparative Study
Female
Hospital Mortality
Humans
Immunization, Passive
Immunoglobulins
Infectious disease
Journal Article
Male
Middle Aged
New York City
Propensity Score
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Retrospective Studies
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Treatment Outcome

Notes:

Date Completed 08.03.2021

Date Revised 12.03.2021

published: Electronic

UpdateOf: medRxiv. 2020 Dec 04;:. - PMID 33300012

Citation Status MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1172/jci.insight.142270

PMID:

33476300

PPN (Catalogue-ID):

NLM321418328